Stephen Anthony Strickland

Stephen Anthony Strickland

Auto-generated profile, based on publicly available information

Stephen Anthony Strickland

Vanderbilt-Ingram Cancer Center, Nashville, TN

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2012 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
MOMargaret R. O'DOnnell
Margaret R. O'DOnnell
CACamille N. Abboud
Camille N. Abboud
JAJessica Altman
Jessica Altman
FAFrederick R. Appelbaum
Frederick R. Appelbaum
DADaniel A. Arber
Daniel A. Arber
KGKristina M. Gregory
Kristina M. Gregory
Acute myeloid leukemia (AML) remains the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML provide recommendations on the diagnostic evaluation and workup for AML, risk assessment based on cytogenetic and molecular features, treatment options for induction and consolidation therapies for younger and older (age ≥ 65 years) adult patients, and key supportive care considerations.

31 January 2022 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Open access
SSStephen A. Strickland
Stephen A. Strickland
NVNorbert Vey
Norbert Vey
Therapy-related acute myeloid leukemia (t-AML), defined as AML arising from prior cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, accounts for 7 %-8 % of AML cases and primarily occurs in elderly patients. t-AML is associated with an increased probability of adverse cytogenetics and shortened survival compared with de novo AML. Factors predicting poorer prognosis in t-AML include older age, unfavorable karyotype, presence of certain mutations, poor performance status, and poor bone marrow reserve. Few clinical studies have focused specifically on patients with t-AML, and the choice of induction therapy for t-AML is thus typically based on subset analyses of larger studies or on extrapolation. In patients deemed fit, t-AML treatment can involve CPX-351 (liposomal daunorubicin and cytarabine) or conventional chemotherapy, ideally followed by hematopoietic cell transplantation. Patients who are not candidates for intensive therapy may benefit from lower-intensity therapies. Additional agents and combination regimens are being evaluated in clinical studies.

9 February 2023 in Blood
Verified
Journal Article
Closed access
PDF file
NPNaveen Pemmaraju
Naveen Pemmaraju
HKHagop M. Kantarjian
Hagop M. Kantarjian
KSKendra L Sweet
Kendra L Sweet
EWEunice S. Wang
Eunice S. Wang
JSJayastu Senapati
Jayastu Senapati
ALAndrew A Lane
Andrew A Lane
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BPDCN can also invade other extramedullary compartments, including the central nervous system. Generally affecting older adults, many patients are unfit to receive intensive chemotherapy, and although hematopoietic stem cell transplantation is preferred for younger, fit individuals, not all are eligible. One recent therapeutic breakthrough is that all BPDCNs express CD123 (IL3Rα) and that this accessible surface marker can be pharmacologically targeted. The first-in-class agent for BPDCN, tagraxofusp, which targets CD123, was approved in December 2018 in the United States for patients with BPDCN aged ≥2 years. Despite favorable response rates in the frontline setting, many patients still relapse in the setting of monotherapy, and outcomes in patients with relapsed/refractory BPDCN remain dismal. Therefore, novel approaches targeting both CD123 and other targets are actively being investigated. To begin to formally address the state of the field, we formed a new collaborative initiative, the North American BPDCN Consortium (NABC). This group of experts, which includes a multidisciplinary panel of hematologists/oncologists, hematopoietic stem cell transplant physicians, pathologists, dermatologists, and pediatric oncologists, was tasked with defining the current standard of care in the field and identifying the most important research questions and future directions in BPDCN. The position findings of the NABC’s inaugural meetings are presented herein.

31 May 2010 in Haematologica
Verified
Journal Article
Open access
PDF file
WCW. B. Clark
W. B. Clark
SSS. A. Strickland
S. A. Strickland
ABA. J. Barrett
A. J. Barrett
BSB. N. Savani
B. N. Savani
Allogeneic stem cell transplant is a potentially curative treatment for patients with acute myeloblastic leukemia and myelodysplastic syndrome. In this issue of the journal, Craddock et al. [1][1] report the largest reported series of T-cell depleted reduced intensity stem cell transplant for acute

4 June 2012 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
SSS M Sengsayadeth
S M Sengsayadeth
MJM Jagasia
M Jagasia
BEB G Engelhardt
B G Engelhardt
AKA Kassim
A Kassim
SSS A Strickland
S A Strickland
BSB N Savani
B N Savani

1 November 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
HKHagop Kantarjian
Hagop Kantarjian
SFStefan Faderl
Stefan Faderl
GGGuillermo Garcia-Manero
Guillermo Garcia-Manero
SLSelina Luger
Selina Luger
PVParameswaran Venugopal
Parameswaran Venugopal
WPWilliam Plunkett
William Plunkett